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Abstract
Background: Infliximab, a chimeric anti-tumour necrosis
factor monoclonal antibody with potent anti-inflammato-
ry effects, represents an effective treatment option in
patients with severe inflammatory bowel disease (IBD).
Serious side-effects of such an immunomodulating ther-
apy are speculated and therefore we reviewed our clini-
cal experience in a retrospective safety study looking
upon a single cohort of 100 IBD patients from a large Ger-
man University Hospital. Methods: 100 patients with
severe Crohn’s disease (n = 92), ulcerative colitis (n = 7)
or indeterminate colitis (n = 1) treated with infliximab
(5 mg/kg) from January 2000 to December 2003 were ret-
rospectively analysed for acute and subacute adverse
events by chart review. Results: Overall, infliximab ther-
apy was generally well tolerated. No fatal complications,
malignancies, autoimmune diseases, neurologic or car-
diovascular complications were observed in the cohort
during the study period. Overall, adverse events were
observed in 10 patients: 2 patients showed an acute infu-
sion reaction, 1 patient a serum sickness-like reaction, in
4 patients a bacterial or viral infection occurred, in 1
patient pancytopenia and 2 patients developed surgical
complications. Only 6 patients with adverse events re-
quired admission to hospital. A case of tuberculosis after
infliximab was not found. The lack of adverse side-
effects was associated with young median age and infre-
quent comorbidities of the cohort. Conclusion: Regard-
ing its strong immunomodulating capacity, infliximab
appears to be an efficient and relatively safe therapeutic
option for patients with severe IBD. However, the use of
infliximab requires careful screening and close patient
monitoring to identify patients at risk and the infrequent,
but sometimes serious complications of infliximab.
Copyright © 2004 S. Karger AG, Basel
Introduction
Infliximab is a chimeric monoclonal antibody com-
prised of 75% human and 25% murine sequences, bind-
ing with a high specificity and affinity to tumour necrosis
factor (TNF)-· and thereby neutralising its immunologi-
cal effects. TNF-· plays a pivotal role in the pathogenesis
of mucosal inflammation in inflammatory bowel disease
(IBD) [1]. The clinical efficacy of infliximab in the treat-
ment of moderate to severe Crohn’s disease, fistulae or
steroid-refractory patients has been shown in several con-
trolled clinical trials [2–6]. Furthermore, a major benefit
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for quality of life [7] and extra-intestinal manifestations in
Crohn’s disease [8–10] has been described.
Since TNF-· represents an important cytokine in the
inflammatory response, the consequences of pharmaco-
logically blocking its physiological functions raise serious
concerns. Potential side-effects are tuberculosis [11], in-
fections or hypersensitivity reactions [12, 13], malignancy
or autoimmune disease [14]. Thus, the safety aspects of
infliximab are of special interest. Although infliximab
showed an acceptable safety profile in both premarketing
and large clinical trials [2, 3, 15–21], there is an obvious
need for further investigator publications on safety as-
pects resulting from growing experience in practice. We
therefore performed a retrospective safety study on a sin-
gle cohort of 100 IBD patients treated by us with inflixi-
mab. The patients were treated in our IBD out-patient
clinic situated in a large academic setting.
Methods
Our survey included 100 IBD patients treated with infliximab at
the Department of Internal Medicine II, Klinikum Grosshadern,
University of Munich, Munich, Germany, between January 2000
and December 2003. Medical records of every patient in this study
were reviewed for the following information: sex, age, diagnosis,
duration of disease, previous medical history (including data on car-
diovascular or pulmonary disease, neurologic disorders, autoim-
mune disease, cancer, dysplasia and infections), anatomic location of
Crohn’s disease or ulcerative colitis, endoscopic and laboratory
results, previous treatment strategies, concomitant medication (cor-
ticosteroids, azathioprine, 6-mercaptopurine, methotrexate, mesas-
alazine), indication for infliximab administration and time and num-
ber of infliximab infusions. Complete medical files were available for
all patients. Summary statistics for categorical variables were ex-
pressed as number (+ percentage); summary statistics for continuous
variables were expressed as mean (+ range) where appropriate.
In all patients, a careful patient interview and examination were
performed prior to treatment by a senior gastroenterologist. Our
screening protocol was prompted by recommendations from the lit-
erature [17–20]. According to safety recommendations, patients with
underlying infection or neoplasia, heart or lung disease or neurologic
disorders were excluded from infliximab therapy. Our screening pro-
tocol further included a tuberculosis skin testing (0.1 ml s.c.) and an
obligatory chest X-ray in order to exclude previous or present tuber-
culosis before starting the treatment. In addition, all patients with
abdominal pain, elevated white blood cell count or C-reactive pro-
tein level underwent a CT or MRI of the abdomen excluding an
intra-abdominal abscess formation. Infection with Clostridium diffi-
cile was excluded by stool microbiology. Female patients at birth-
giving age were informed about the need of birth control.
Infliximab (Remicade; Centocor Inc., Malvern, Pa., USA) was
administered in patients with active fistulizing Crohn’s disease,
active luminal Crohn’s disease refractory to conservative treatment
or in a rescue approach in patients with severe steroid-refractory
ulcerative colitis or indeterminate colitis in a 2-hour intravenous
infusion at a dose of 5 mg/kg. All infusions of infliximab were admin-
istered to hospital in-patients or out-patients at the Department of
Internal Medicine II, Grosshadern, University of Munich. The staff
is fully trained in the administration of infliximab infusions. During
the infusion, vital parameters were checked every 30 min. In case of
an adverse event, a senior gastroenterologist was called and the event
and the action taken were documented in the medical file.
All patients in the out-patient clinic stayed for 2 h after the infu-
sion with repeated controls of vital parameters. They reported to the
physician 48 h after infusion by telephone. For follow-up, patients
were seen and examined in the out-patient department and lab con-
trols were performed on a regular base in order to assess efficacy and
long-term safety. Clinical remission for patients with Crohn’s disease
was defined as a Crohn’s disease activity index of ^150 in patients
with steroid-refractory active Crohn’s disease or as closure of drain-
ing fistulae at week 8.
Results
Patient Characteristics
A total of 100 patients met the eligibility criteria for
this retrospective cohort study. The study population con-
sisted of 54 male and 46 female patients at the median age
of 36 (range 18–65), in which Crohn’s disease (n = 92),
ulcerative colitis (n = 7) or indeterminate colitis (n = 1)
was diagnosed by clinical parameters, laboratory results
and endoscopic/histologic findings (table 1). No children
or adolescents under the age of 18 were included. The
median follow-up after the last infliximab infusion was 26
months (range 3–48 months) with only 3 patients (3%)
having !6 weeks of follow-up. Eighty-two of 100 patients
received concomitant immunosuppressive medication
(azathioprine, n = 64; 6-mercaptopurine, n = 18), mesasal-
azine (n = 10) or corticosteroids (n = 42).
Results of Patient Screening
As a result of our intensified safety protocol prior to
treatment, 2 patients were shown to have positive test
results for tuberculosis skin tests and were therefore
excluded from infliximab therapy. Fourteen patients were
shown to have an intra-abdominal abscess or an intestinal
stenosis in CT or MRI and therefore had to undergo sur-
gery or antibiotic treatment. All these patients showed an
elevated C-reactive protein level or white blood cell count
and a significant clinical history of abdominal pain or
fever. Of the 14 patients initially excluded from infusion
therapy, 6 patients received infliximab in their further
medical course after completion of surgical or antibiotic
treatment. In all 6 patients, no complications were ob-
served.
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Infliximab Therapy
Infliximab was given to patients with active fistulizing
Crohn’s disease or active luminal Crohn’s disease refrac-
tory to conservative treatment, intolerant to immunosup-
pressive therapy or with contraindications to steroids (n =
92; table 1). In addition, our cohort included a small num-
ber of patients with severe steroid-refractory ulcerative
colitis (n = 7) or indeterminate colitis (n = 1). Overall, a
total of 322 infusions was given in 100 patients (median
number of infusions 3, range 1–7). Ninety-two patients
received an infliximab infusion at weeks 0, 2 and 6 follow-
ing the three-dose induction regimen, 8 patients only had
a single infusion for induction. Eighty-six of the 100
patients treated (86%) were shown to be in clinical remis-
sion after induction therapy (week 8). Fifteen patients
required repeated infliximab infusions in an on-demand
maintenance therapy regimen (4–7 times); 71 patients
stayed in remission on immunosuppressive medication
(azathioprine or 6-mercaptopurine). Reduction or cessa-
tion of steroids was possible in 38 patients.
Adverse Events
Overall, infliximab therapy was well-tolerated in 90 of
100 patients (90%). Serious adverse events were infre-
quent. In our cohort, no fatal complication, malignancy or
neurologic or cardiovascular complication was noted dur-
ing the observation period; furthermore, no new onset of
autoimmune disease was diagnosed. Adverse events doc-
umented in the observation period occurred in 10 of 100
patients (10%), including 2 patients with acute infusion
reactions (2%), 1 patient with a mild serum sickness-like
reaction (1%), 4 patients with bacterial or viral infections
(4%), 2 patient with surgical complications (2%) and 1
patient with pancytopenia (1%) (table 2). However, 5
adverse events reported below in detail (5%) have to be
critically reviewed in their relation to infliximab analys-
ing parameters like the time interval between therapy and
the onset of side-effects or concomitant medication. Over-
all, 6 events were classified as serious adverse events
requiring admission to hospital (6%). All adverse events
were successfully managed with medication and without
sequelae.
Infusion Reactions and Serum Sickness-Like Disease
In our cohort, we observed 2 patients with acute infu-
sion reactions and 1 patient with serum sickness-like dis-
ease associated with infliximab therapy, leading to dis-
continuation of the infusion in 2 patients. None of the
events was life-threatening, epinephrine did not have to
be administered and the use of treatment protocols (see
Table 1. Patient characteristics (n = 100)
Male/female 54/46
Median age 36 (18–65)
Duration of IBD, years 8.4 (1–24)
IBD subtype
Crohn’s disease
Ulcerative colitis
Indeterminate colitis 
92 (92%)
7 (7%)
1 (1%)
Disease location of Crohn’s disease
Terminal ileum only
+ Colon
+ Oesophageus/stomach
65
18
9
Disease location of ulcerative colitis
Rectum only
Left-sided colitis
Pancolitis
3
2
2
Indication for infliximab therapy
Refractory Crohn’s disease
Intolerance to immunosuppression
Contraindications to steroids
Steroid-refractory ulcerative colitis
Steroid-refractory indeterminate colitis
72
4
16
7
1
Median follow-up after the last infliximab infusion,
months 26 (3–48)
Concomitant medication at time of first infliximab infusion
Azathioprine
6-Mercaptopurine
Mesasalazine
Corticosteroids
64
18
10
42
below for details) resulted in a rapid resolution of all acute
reactions to infliximab. In both patients with infusion
reactions, the event had occurred despite being on con-
comitant immunosuppressive medication (azathioprine)
for 16 months.
A 29-year-old male patient with Crohn’s disease had a
mild acute infusion reaction with urticaria during the sec-
ond infusion of infliximab (week 2 of three-dose induc-
tion regimen), which resolved after symptomatic treat-
ment (diphenhydramine). The infusion was continued
without complications and no hospital admission was
required. The patient was successfully reinfused in week
6, administrating premedication with corticosteroids.
A 30-year-old female patient with severe fistulizing
Crohn’s disease developed a moderate acute hypersensi-
tivity reaction with flush, urticaria and pruritus during
the 6th infusion of infliximab; the infusion was imme-
diately stopped and the patient recovered soon after out-
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Table 2. Patients with side-effects of infliximab therapy
Pa-
tient
No.
Sex Age Diagnosis Adverse event Time
interval
Infusions Concomitant
medication
1 m 29 CD acute infusion reaction minutes 2 azathioprine
2 f 30 CD acute infusion reaction minutes 6 azathioprine
3 f 21 CD serum sickness-like reaction 5 days 3 10 mg prednisone
4 m 22 CD varicella-zoster infection 1 week 1 azathioprine
5 m 51 CD bacterial pneumonia 3 weeks 2 6-mercaptopurine
6 m 45 CD acute pyelonephritis 6 months 4 azathioprine
7 f 30 CD tonsillar abscess/sepsis 3 months 1 azathioprine
8 m 54 CD surgical complications 3 weeks 3 30 mg prednisone
9 f 40 CD surgical complications 2 weeks 1 20 mg prednisone
10 f 32 IC pancytopenia 6 days 1 antibiotics,
50 mg prednisone
CD = Crohn’s disease; IC = indeterminate colitis.
patient treatment with corticosteroids and diphenhy-
dramine. This patient had never experienced any infusion
reactions before; the time since the last infusion was 4
years. So far, no reinfusion of infliximab has been admin-
istered in this patient due to safety issues.
In addition, a 21-year-old female patient with active
luminal Crohn’s disease developed a serum sickness-like
disease 5 days after the third infliximab infusion (week 6
of induction regimen) with pruritus, rash and myalgia,
which resolved after symptomatic treatment in the out-
patient department (corticosteroids) and no hospital ad-
mission was required. The patient refused reinfusion of
infliximab.
Infections
Overall, we observed 4 events with bacterial or viral
infections in our study population (4%). None of the
infectious complications described were fatal. In the co-
hort, no intra-abdominal abscess, opportunistic infection
or cutaneous infection was observed.
A 22-year-old male patient with Crohn’s disease devel-
oped for the first time in his life a generalized infection
with varicella-zoster virus 1 week after the first infusion of
infliximab. After symptomatic treatment for pruritus in
the out-patient clinic, the patient soon recovered without
further complications.
A 51-year-old male patient with Crohn’s disease
showed an acute onset of bacterial uncomplicated pneu-
monia 3 weeks after the second infusion of infliximab
(week 2 of induction regimen), which resolved soon after
antibiotic treatment in the hospital.
A 45-year-old male patient with severe fistulizing
Crohn’s disease and a known enterovesicular fistula was
found to have acute pyelonephritis (Escherichia coli) 6
months after the 4th infliximab infusion requiring long-
standing antibiotic treatment. The patient had been on
concomitant immunosuppressive therapy with azathio-
prine for 18 months.
A 30-year-old female patient with Crohn’s disease was
admitted to hospital due to a severe generalized sepsis 3
months after the first infusion of infliximab, requiring
intensive care treatment with intubation. The focus of the
sepsis was a tonsillar abscess and the patient recovered on
antibiotic treatment without further complications. The
patient had been on concomitant immunosuppressive
therapy with azathioprine for 12 months.
Surgical Complications
A 54-year-old male patient (Crohn’s disease) of the
cohort underwent surgery (ileocoecal resection) 3 weeks
after the 3rd infusion of infliximab and showed marked
insufficiency of the surgical anastomosis requiring two
surgical revisions. The patient had been on concomitant
steroids (30 mg prednisone/day).
A 40-year-old female patient (Crohn’s disease) under-
went ileocoecal resection 2 weeks after the 1st infusion of
infliximab. The patient, who was on concomitant steroids
(20 mg prednisone/day) at the time of surgery, required
two surgical revisions due to repeated surgical insuffi-
ciency.
Safety Aspects of Infliximab in IBD
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Bone Marrow Toxicity
In a 32-year-old female patient with indeterminate
colitis who received one infusion with infliximab in a res-
cue approach, we observed marked pancytopenia over 2
weeks, requiring blood transfusions and G-CSF. The pa-
tient recovered after 3 weeks and underwent total colecto-
my without complication. The pancytopenia retrospec-
tively started 6 days after the infliximab infusion; how-
ever, the patient also received 2 different intravenous
antibiotics of which one was started 2 days before the pan-
cytopenia occurred. In summary, it remains unclear
whether the infliximab therapy or antibiotic treatment
has caused this serious complication. Investigations for
viral infection or malignancy showed no pathological
finding; furthermore, no antinuclear antibodies, anti-dou-
ble-stranded DNA or parameters of hemolysis were
found.
Additional Information
No onset of autoimmune disease, malignancy or death
was observed during the observation period. None of the
patients in our cohort became pregnant during the obser-
vation period.
Evaluation of Risk Factors
Regarding the potential need of developing a risk pro-
file predicting adverse events, data like gender, age, con-
comitant medication, duration of disease, number of
infliximab infusions, time interval between infliximab
infusions, allergies in the medical history and level of anti-
nuclear antibodies were evaluated. Analysing our patient
cohort, none of the risk factors evaluated was found to be
statistically significant due to the limited number of
patients with adverse events.
Discussion
The purpose of our retrospective cohort study was to
evaluate the safety profile of infliximab in clinical prac-
tice in our IBD patients over a time period of 4 years. Our
experience demonstrates that infliximab is an effective
and safe treatment option in daily clinical practice if care-
ful patient screening and observation is guaranteed.
In comparison to other clinical studies published, it is
of note that there were no fatal complications in our
cohort and that the overall rate of serious adverse events
related to infliximab (6%) was remarkably low [2, 17–20].
Reviewing data from different academic settings, report-
ing a mortality rate of up to 1% and higher incidences of
serious adverse events [2, 17], the careful patient screen-
ing and thorough exclusion criteria of our centre may
have prevented complications to a higher rate than pub-
lished before. In addition, it has to be emphasized that
patients in our cohort were younger (similar median, but
different range, with no patient being 165 years) and care-
fully selected for comorbidities, which are known to be
contributing risk factors for mortality. Analysing reports
of IBD patients dying after infliximab therapy published
so far [2, 17], comorbidites and old age are a major risk
factor. This fact stresses the importance of special caution
in infliximab therapy in elderly persons or patients with
associated medical problems and may implicate im-
proved criteria for patient selection. An additional expla-
nation for the small number of adverse events in our
cohort may also be the limited number of patients on
maintenance infliximab therapy (n = 15).
Also, there have been ongoing concerns about inflixi-
mab and its risk of inducing lymphoproliferative disor-
ders or other malignancies on a long-term base. In our
study on safety data summarizing 4 years of follow-up, no
signs or parameters suggestive of neoplasia or lympho-
proliferative disorder have been observed. These data are
in line with results of large controlled trials, in which no
increased incidence of malignancy in individuals treated
with infliximab had been found [21]. Although these
results are definitively reassuring, more data on long-term
safety are clearly required.
Regarding the significant risk of tuberculosis after
infliximab therapy documented in previous studies and
reviews on patients with Crohn’s disease or rheumatoid
arthritis [11, 22], it is of note that there was no onset of
tuberculosis in our cohort. Although this study was per-
formed in a regional area with a low incidence of tubercu-
losis [23], 2 patients were found to have positive tubercu-
losis test results by screening prior to treatment and were
excluded from infliximab therapy. Since tuberculin tests
may produce false-negative results in patients on immu-
nosuppressive medication, a careful risk assessment and
appropriate patient screening for tuberculosis (skin test
with 0.1 ml s.c. and chest X-ray) should be routinely taken
into consideration in the approach towards patients with
Crohn’s disease prior to infliximab infusion.
Intensified patient screening by radiologic imaging was
of high value in patients with abdominal pain, fever or
elevated white blood cell/C-reactive protein level, in
which a CT or MRI was performed as part of our safety
protocol. Overall, 14 patients had to be excluded from
infliximab therapy due to an abscess or intestinal stenosis
diagnosed by careful screening; 6 of these 14 patients
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received infliximab after successful surgical drainage and
antibiotic treatment without further complications. As a
result, none of the 100 patients analysed in our retro-
spective study showed an adverse event due to an intra-
abdominal abscess or related complications. Previous
data from other cohort studies reported on patients with
intra-abdominal abscesses or small bowel obstructions
who were even dying after infliximab therapy [2, 17].
Based upon our data, we propose that careful medical
screening and radiologic imaging is of high value in such
patients with suspected intra-abdominal abscess or intes-
tinal stenosis.
In our study population, viral or bacterial infections
occurred in 4%. This is a remarkably low frequency com-
pared to data from the ACCENT I trial where 32% of
patients had infections requiring antibiotic treatment [2].
In addition, we did not observe any clinically relevant
opportunistic infections like candida, listeriosis, histo-
plasmosis, aspergillosis or pneumocystis carinii pneumo-
nia in contrast to previous trials [11]. This fact might also
well be explained by our patient demographics (age,
comorbidities) and the intensified safety protocol. Im-
pressed by the 45-year-old male patient with severe fistu-
lizing disease and developing acute pyelonephritis, we
underline that enterovesicular fistulae are a risk factor in
infliximab therapy. Still in this case, infliximab was prob-
ably not the proven cause. In Crohn’s disease patients
with known moderate to severe enterovesicular fistulae,
regular urine analysis and prophylactic antibiotic treat-
ment should be considered as a standard in the infliximab
safety protocol.
Acute infusion reactions occurred in 2% of all patients
(n = 2), representing a lower frequency than observed in
other clinical studies. This might also be related to the fact
that only a small number of patients of our cohort
received infliximab as a maintenance therapy. Both
events reported were classified as mild to moderate and as
not life-threatening complication. Given the high number
of patients in our cohort on concomitant long-term immu-
nosuppressive therapy started prior or at the time of
infliximab therapy, this result is consistent with data from
clinical studies indicating that a concomitant immuno-
suppressive therapy is proven to reduce the risk of infu-
sion reactions [24–26]. However, given the fact that both
patients in whom infusion reactions occurred had been on
long-standing azathioprine medication, coadministration
of immunosuppressive therapy may lower but not com-
pletely prevent the risk of infusion reactions. Regarding
the 30-year-old female patient who had a moderate infu-
sion reaction, the long time interval since the last inflixi-
mab infusion (4 years) might be considered as a risk factor
for developing infusion reactions. Although there are
reports of successful readministration of infliximab in
patients with a history of infusion reactions [27], the
patient had no reinfusion due to safety reasons.
Serum sickness-like reactions classified as a mild ad-
verse event occurred in 1 patient (1%), reporting pruritus,
rash and myalgias, which soon resolved after symptomat-
ic treatment. This percentage is in line with the incidence
observed in large clinical trials (2% in the ACCENT I
trial) [2]; however, in our study, there might be a tendency
of patients to underreport mild symptoms like myalgias or
arthralgias to their physicians so that further studies on
the frequency and risk factors of serum sickness-like dis-
ease after infliximab therapy are required.
A 32-year-old female patient with indeterminate colitis
who received infliximab developed marked pancytopenia
which resolved after 3 weeks. In the ACCENT I mainte-
nance trial and postmarketing surveillance data, there were
no similar reports [2, 17–20]. However, case reports from 2
patients with rheumatoid arthritis or scleroderma have
shown serious pancytopenia after infliximab infusion [28,
29]. Although it will remain unclear whether the concomi-
tant antibiotic therapy or the underlying inflammatory dis-
ease itself has caused this adverse event [30, 31], further
investigations on bone marrow toxicity caused by inflixi-
mab therapy are required. This adverse event also points to
the need of further controlled clinical studies on infliximab
in the therapy of indeterminate colitis.
Regarding the 2 patients with complications after sur-
gery, the concomitant use of high doses of steroids most
likely seems to have caused these adverse events. How-
ever, further controlled clinical trials on the effect of
infliximab therapy on the outcome of surgical interven-
tions in IBD patients are required.
Conclusion
The results of this retrospective single cohort study
show that infliximab is an effective and relatively well-
tolerated treatment option for patients with active lumi-
nal or fistulizing Crohn’s disease with an acceptable short-
term and long-term safety profile. Our data confirm that
careful patient screening and selection as well as a vigilant
approach towards theoretical risks are required in using
this promising therapy. In conclusion, our study provides
more data on safety aspects using infliximab in IBD
patients and valuable information for improving screen-
ing protocols.
Safety Aspects of Infliximab in IBD
Patients
Digestion 2004;70:3–9 9
References
1 Podolsky DK: Inflammatory bowel disease. N
Engl J Med 2002;347:417–429.
2 Hanauer SB, Feagan BG, Lichtenstein GR,
Mayer LF, Schreiber S, Colombel JF, Rachmi-
lewitz D, Wolf DC, Olson A, Bao W, Rutgeerts
P: Maintenance infliximab for Crohn’s disease:
The ACCENT I randomised trial. Lancet 2002;
359:1541–1549.
3 Sandborn WJ, Feagan BG, Hanauer SB,
Present DH, Sutherland LR, Kamm MA, Wolf
DC, Baker JP, Hawkey C, Archambault A,
Bernstein CN, Novak C, Heath PK, Targan
SR; CDP571 Crohn’s Disease Study Group:
An engineered human antibody to TNF
(CDP571) for active Crohn’s disease: A ran-
domized double-blind placebo-controlled trial.
Gastroenterology 2001;120:1330–1338.
4 Present DH, Rutgeerts P, Targan S, Hanauer
SB, Mayer L, van Hogezand RA, Podolsky DK,
Sands BE, Braakman T, DeWoody KL, Schai-
ble TF, van Deventer SJ: Infliximab for the
treatment of fistulas in patients with Crohn’s
disease. N Engl J Med 1999;340:1398–1405.
5 D’Haens GR: Infliximab as disease-modifying
therapy. Eur J Gastroenterol Hepatol 2003;15:
233–237.
6 Ochsenkühn T, Göke B, Sackmann M: Com-
bining infliximab with 6-mercaptopurine/aza-
thioprine for fistula therapy in Crohn’s disease.
Am J Gastroenterol 2002;97:2022–2025.
7 Lichtenstein GR, Bala M, Han C, DeWoody K,
Schaible T: Infliximab improves quality of life
in patients with Crohn’s disease. Inflamm
Bowel Dis 2002;8:237–243.
8 Grange F, Djialali-Bouzina F, Weiss AM, Po-
lette A, Guillaume JC: Corticosteroid-resistant
pyoderma gangrenosum associated with
Crohn‘s disease: Rapid cure with infliximab.
Dermatology 2002;205:278–280.
9 Herfarth H, Obermeier F, Andus T, Rogler G,
Nikolaus S, Kuehbacher T, Schreiber S: Im-
provement of arthritis and arthralgia after
treatment with infliximab (Remicade) in a
German prospective, open-label, multicenter
trial in refractory Crohn’s disease. Am J Gas-
troenterol 2002;97:2688–2690.
10 Fries W, Giofre MR, Catanoso M, Lo Gullo R:
Treatment of acute uveitis associated with
Crohn’s disease and sacroileitis with inflixi-
mab. Am J Gastroenterol 2002;97:499–500.
11 Keane J, Gershon S, Wise RP, Mirabile-Levens
E, Kasznica J, Schwieterman WD, Siegel JN,
Braun MM: Tuberculosis associated with in-
fliximab, a tumor necrosis factor alpha-neutral-
izing agent. N Engl J Med 2001;345:1098–
1104.
12 Riegert-Johnson DL, Godfrey JA, Myers JL,
Hubmayr RD, Sandborn WJ, Loftus EV Jr:
Delayed hypersensitivity reaction and acute re-
spiratory distress syndrome following inflixi-
mab infusion. Inflamm Bowel Dis 2002;8:186–
191.
13 Ritz MA, Jost R: Severe pneumococcal pneu-
monia following treatment with infliximab for
Crohn’s disease. Inflamm Bowel Dis 2001;7:
327.
14 Ali Y, Shah S: Infliximab-induced systemic
lupus erythematosus. Ann Intern Med. 2002;
137:625–626.
15 Cheifetz A, Smedley M, Martin S, Reiter M,
Leone G, Mayer L, Plevy S: The incidence and
management of infusion reactions to inflixi-
mab: A large center experience. Am J Gas-
troenterol 2003;98:1315–1324.
16 Hommes DW, van Deventer SJ: Infliximab
therapy in Crohn’s disease: Safety issues. Neth
J Med 2003;61:100–104.
17 Colombel JF, Loftus EV Jr, Tremaine WJ,
Egan LJ, Harmsen WS, Schleck CD, Zinsmeis-
ter AR, Sandborn WJ: The safety profile of
infliximab in patients with Crohn’s disease:
The Mayo clinic experience in 500 patients.
Gastroenterology 2004;126:19–31.
18 Ardizzone S, et al.: Infliximab in treatment of
Crohn’s disease: The Milan experience. Dig
Liver Dis 2002 34:411–418.
19 Sample C, et al.: Clinical experience with in-
fliximab for Crohn’s disease: The first 100
patients in Edmonton, Alberta. Can J Gas-
troenterol 2002;16:165–170.
20 Cohen RD: Efficacy and safety of repeated
Infliximab infusions for Crohn’s disease: 1-
Year clinical experience. Inflamm Bowel Dis
2001;7(suppl 1):S17–S22.
21 Hanauer S, Schaible T, DeWoody K, et al:
Long-term follow-up of patients treated with
infliximab in clinical trials. Gastroenterology
2000;18:A566.
22 Baker D, Clark J, Keenan G, Jones S: Tubercu-
losis occurring in patients receiving the anti-
TNF agent infliximab. Arthritis Rheum 2001;
118(suppl):A569.
23 Loddenkemper R, Brendel A, Sagebiel D,
Forssbohm M: The state of tuberculosis in Ger-
many in 2000. Pneumologie 2002;56:550–
557.
24 Hanauer SB: Immunogenicity of infliximab in
Crohn’s disease. N Engl J Med 2003;348:2155–
2156.
25 Baert F, Noman M, Vermeire S, et al: Influence
of the immunogenicity on the long-term effica-
cy of infliximab in Crohn’s disease. N Engl J
Med 2003;348:601.
26 Sandborn WJ: Preventing antibodies to inflixi-
mab in patients with Crohn’s disease: Optimize
not immunize. Gastroenterology 2003;124:
1140–1145.
27 Puchner TC, Kugathasan S, Kelly KJ, et al:
Successful desensitization and therapeutic use
of infliximab in adult and pediatric Crohn’s
disease patients with prior anaphylactic reac-
tion. Inflamm Bowel Dis 2001;7:34–37.
28 Menon Y, Cucurull E, Espinoza LR: Pancyto-
penia in a patient with scleroderma treated
with infliximab. Rheumatology 2003;42:193–
194.
29 Marchesoni A, Arreghini M, Panni B, Battafa-
rano N, Uziel L: Life-threatening reversible
bone marrow toxicity in a rheumatoid arthritis
patient switched from leflunomide to inflixi-
mab. Rheumatology (Oxford) 2003;42:1273–
1274.
30 Jani AL, Hamilos D: Bloody diarrhea, fever
and pancytopenia in a patient with active ulcer-
ative colitis. Ann Allergy Asthma Immunol
2003;90:383–388.
31 Sijpkens YW, Allaart CF, Thompson J, van‘t
Wout J, Kluin PM, den Ottolander GJ, Bieger
R: Fever and progressive pancytopenia in a 20-
year old woman with Crohn’s disease. Ann
Hematol 1996;72:286–290.
